UK markets close in 8 hours 9 minutes
  • FTSE 100

    5,539.74
    -42.01 (-0.75%)
     
  • FTSE 250

    17,052.80
    -124.88 (-0.73%)
     
  • AIM

    946.47
    -2.83 (-0.30%)
     
  • GBP/EUR

    1.1069
    +0.0005 (+0.05%)
     
  • GBP/USD

    1.2927
    +0.0004 (+0.03%)
     
  • BTC-GBP

    10,304.35
    -38.25 (-0.37%)
     
  • CMC Crypto 200

    260.83
    +18.15 (+7.48%)
     
  • S&P 500

    3,310.11
    +39.08 (+1.19%)
     
  • DOW

    26,659.11
    +139.16 (+0.52%)
     
  • CRUDE OIL

    36.13
    -0.04 (-0.11%)
     
  • GOLD FUTURES

    1,874.20
    +6.20 (+0.33%)
     
  • NIKKEI 225

    22,977.13
    -354.81 (-1.52%)
     
  • HANG SENG

    24,073.72
    -512.88 (-2.09%)
     
  • DAX

    11,464.77
    -133.30 (-1.15%)
     
  • CAC 40

    4,528.43
    -41.24 (-0.90%)
     

Abivax announces the release of its 2020 half-year financial report

·2-min read

DGAP-News: ABIVAX / Key word(s): Half Year Results
30.09.2020 / 18:00
The issuer is solely responsible for the content of this announcement.

Abivax announces the release of its 2020 half-year financial report


PARIS, France, September 30, 2020 - 06:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces the publication of its 2020 half-year financial report. This document is available in electronic version on the website of the company (www.abivax.com) and on the website of the French financial markets authority, AMF (www.amf-france.org).


About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Abivax is listed on Euronext compartment C (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.

More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.

******

Contacts


30.09.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Abivax
Finance Department
Didier Blondel
didier.blondel@abivax.com
+33 1 53 83 08 41

Investors
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254

Press Relations & Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22


Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24


Public Relations France
DGM Conseil
Thomas Roborel de Climens
thomasdeclimens@dgm-conseil.fr
+33 6 14 50 15 84


Public Relations USA
Rooney Partners LLC
Marion Janic
mjanic@rooneyco.com
+1 212 223 4017

Abivax
Finance Department
Didier Blondel
didier.blondel@abivax.com
+33 1 53 83 08 41

Investors
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254

Press Relations & Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22


Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24


Public Relations France
DGM Conseil
Thomas Roborel de Climens
thomasdeclimens@dgm-conseil.fr
+33 6 14 50 15 84


Public Relations USA
Rooney Partners LLC
Marion Janic
mjanic@rooneyco.com
+1 212 223 4017

show this
show this